Cisplatin (CP) is the primary standard treatment for bladder cancer. Nevertheless, CP has side effects, particularly nephrotoxicity. This limits the treatment of a notable portion of advanced bladder cancer patients with cisplatin. We have developed gold nanoparticles that conjugate CP (CP-AuNPs) for safer delivery to tumors. Here, we investigated the biodistribution of the CP-AuNP conjugates in a mouse model of bladder cancer, to characterize the distinct role of CPAuNP in delivering and releasing CP in tumor and tissues. Effect of the CP-AuNPs on weight and kidney was also investigated. This study can provide insights into the potential safety of CP-AuNP for bladder cancer treatment.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.